GSK in the 13F filings
GSK PLC · CUSIP 37733W204
- Quarter end
- 30 Sep 2026
- the date the book describes
- Filed
- 9 Nov 2026
- latest of these filings; the earliest 9 Nov 2026
- Managers listing it
- 1
- at least, of 95 tracked, among listed positions
- Comparable managers
- 5
- filed both Q2 2026 and Q3 2026; 1 listed it in both
- Shares listed
- 4,554,598
- combined, among listed positions
- Reported value
- $219m
- combined, at the quarter end
Among the 5 comparable managers: 0 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -2,163,799.
Managers listing GSK in Q3 2026
1 of 1 holder
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Acadian Asset Management LLC | 4,554,598 | $219m | 0.26% | Trimmed | -2,105,836 | 9 Nov 2026 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
No increase among listed positions.
Reductions
- Acadian Asset Management LLCexisting position · 4,554,598 shares now-2,105,836
New positions and exits
New (0)
No new position among listed positions.
Exited (1)
- Squarepoint Ops LLCwas $3.0m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2022 | 1 | $19m | n.a. | n.a. |
| Q3 2022 | 18 | $3.9bn | n.a. | n.a. |
| Q4 2022 | 18 | $4.9bn | n.a. | n.a. |
| Q1 2023 | 13 | $4.4bn | n.a. | n.a. |
| Q2 2023 | 13 | $4.3bn | n.a. | n.a. |
| Q3 2023 | 16 | $4.5bn | n.a. | n.a. |
| Q4 2023 | 13 | $4.5bn | 6 | 7 |
| Q1 2024 | 13 | $5.3bn | 5 | 7 |
| Q2 2024 | 10 | $4.6bn | 6 | 4 |
| Q3 2024 | 10 | $4.9bn | 6 | 3 |
| Q4 2024 | 13 | $4.9bn | 11 | 2 |
| Q1 2025 | 11 | $6.3bn | 7 | 6 |
| Q2 2025 | 10 | $6.2bn | 8 | 3 |
| Q3 2025 | 11 | $7.5bn | 6 | 5 |
| Q4 2025 | 11 | $8.8bn | 15 | 13 |
| Q1 2026 | 9 | $9.1bn | 9 | 19 |
| Q2 2026 | 11 | $7.5bn | 15 | 12 |
| Q3 2026 | 1 | $219m | 0 | 2 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
GSK and LLY →GSK and JNJ →GSK and VRTX →Choose a stock to compare with GSK →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own GSK, latest filings →Back to the 13F Explorer →